Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCT03160521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

438

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Schizophrenia

Interventions

DRUG: Risperidone ISM 75 mg
DRUG: Risperidone ISM 100 mg
DRUG: Placebo of Risperidone ISM

Sponsor

Rovi Pharmaceuticals Laboratories